These Support PLUS Physician Portal Terms of Use govern your access to these websites and mobile applications controlled by AbbVie Inc., including its subsidiaries and affiliates (together referred to as “AbbVie”), as they relate to Support PLUS Physician Portal (“Support PLUS Physician Portal Websites”). These Terms of Use do not apply to AbbVie websites that do not present or link to these Terms of Use, or to third-party websites to which AbbVie websites may link. Your use of these Support PLUS Physician Portal Websites and mobile applications is subject to these Terms of Use.
Without prejudice to your rights under applicable law, AbbVie reserves the right to amend these Terms of Use to reflect technological advancements, legal and regulatory changes, and good business practices. If AbbVie changes these Terms of Use, an updated version of these Terms of Use will reflect those changes and we will notify you of such changes by updating the effective date at the top of these Terms of Use. If you disagree with these Terms of Use, or are dissatisfied with these Support PLUS Physician Portal Websites, your sole and exclusive remedy is to discontinue using these Support PLUS Physician Portal Websites.
You acknowledge and agree that:
The content on this site is for the purposes expressed in the Business Associates Agreement in place between your medical practice and RxCrossroads By McKesson, Inc. No information provided here should be used as a substitute for medical advice or for purposes of diagnosing a health problem or disease. All decisions regarding patient care should be handled by health care professionals and based on the unique needs of the individual patient.
These Support PLUS Physician Portal Websites incorporate by reference the terms of use from AbbVie.com, as applicable, available here: https://www.abbvie.com/termsofuse.html.
Norditropin® [somatropin (rDNA origin) injection] is indicated for the treatment of pediatric patients with:
Norditropin® is also indicated for the replacement of endogenous GH in adults with growth hormone deficiency (GHD) who meet either of the following two criteria:
Somatropin is contraindicated in: